Embecta Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $334.9M
- Price
- $5.91
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.67%
- Volume
- 994.1K
About
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Quick stats
Shares outstanding56.7M
Computed float56.0M
Float / shares98.8%
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001872789
Websitehttps://www.embecta.com
AI Summary
AI-generated1/50
minorneutrallegal litigation
EMBECTA CORP. (NASDAQ: EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (NASDAQ: EMBC).
The firm is soliciting shareholders who purchased Embecta shares before November 25, 2025 to contact it regarding possible legal remedies.
This is a law-firm advertising solicitation, not a filed lawsuit or company disclosure; no claims have been filed and no court action exists at this stage.